From January 25th until the 27th of January, San Francisco once again formed the background for the yearly high mass in urological cancer. During the 2024 ASCO Genitourinary cancers symposium, the latest clinical and scientific advances in the management of urothelial, prostate, and renal cell cancer were presented. This report will provide a brief overview of the key presentation at this years’ meeting.
(Belg J Med Oncol 2024;18(3):109–14)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
